home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
  HUM-MOLGEN -> Events -> Meetings and Conferences  
 

What are the Scientific Basis of Clinical Research and the hall mark of a good study protocol?

 
  January 03, 2011  
     
 


ComplianceOnline, Online Event
2011-01-07


NOTE: Use This Promocode ( 117660 ) To Get 10% Discount. 

Why Should You Attend:

The basis for determining that a drug or device is “Safe and effective” is a series of scientifically sound, appropriately blinded, statistically relevant, and ethically performed process and it controlled by the Investigators.

This Webinar goes over the scientific standards of the drug development process. Starting with the drug discovery process, the role of the dose response relationship, the role of the IND process is discussed. You will learn the regulations to follow in Phase I and the 6 major questions that must be answered in this Phase.

The determination of the first dose in humans is another critical point in the process. Learn the questions each Phase in the development process must answer and how that is managed.. In the end, it is the Safety or risk and the efficacy or benefit ratio, which must be favorable for the process to continue.

Areas Covered in the Seminar:

  • What is the goal of Preclinical drug development.
  • What do we learn from the Dose-Response relationship.
  • What are the hallmarks of a good study protocol.
  • Who are the main players in the development of safe medicines.
  • How do you chose the starting does for the first-in-man studies.
  • What questions are answered in Phase I Clinical Research.
  • How is the first time in patients (Phase IIa) handled.
  • What is the main goal of Phase III studies.
  • What are the main methodological Issues encountered in Clinical Research.

Who Will Benefit:

This webinar will provide invaluable assistance to investigators and their staff in the regulatory / legal responsibilities and also the ethical considerations in pharmaceutical product (Drug or device) research involving human subjects. Those benefiting the most would be:
  • Principal Investigators / Sub-investigators.
  • Clinical Research Scientists (PKs, Biostatisticians).
  • Safety Nurses.
  • Clinical Research Associates (CRAs) and Coordinators (CRCs).
  • QA / QC auditors and staff.
  • Clinical Research Data managers
 
 
Organized by: ComplianceOnline
Invited Speakers: Charles H. Pierce, MD, PhD, FCP, CPI Has 20+ years experience in the Clinical Research field. He now brings the message (via webinars, lectures and seminars) of Risk Management through knowledge of GCP Regulations and Investigator Responsibility to the entire investigative team to help them understand the regulations as well as the ethics of research involving human subjects. He has been involved in developing Phase I & IIa Clinical Pharmacology Units, Investigator and staff GCP training, and medical monitoring in both drug and device studies.
 
Deadline for Abstracts: 2011-01-07
 
Registration:

Attend Live Online Training

$449.00 One dial in - Unlimited Participation in a conference/ meeting room 

E-mail: admin@complianceonline.com
 
   
 
home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
 
 

Generated by meetings and positions 5.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995- HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.